Last updated: June 2, 2026
ROBAXIN-750 (methocarbamol 750 mg) clinical trials update, market analysis, and projection
Executive summary: ROBAXIN-750 (methocarbamol 750 mg, oral) is an older, widely distributed generic muscle relaxant with limited presence in late-stage clinical trials compared with newer branded specialty therapies. Commercial outlook is driven by (1) steady demand from low-acuity musculoskeletal care, (2) erosion from multi-source generic methocarbamol, and (3) periodic formulary and payer contracting rather than patent-led exclusivity expansion. Near-term growth is expected to track overall generics and muscle-relaxant market dynamics, not new-drug launches.
What is ROBAXIN-750 and what active ingredient does it contain?
Featured snippet answer: ROBAXIN-750 is oral methocarbamol 750 mg, used for relief of discomfort associated with acute, painful musculoskeletal conditions (as an adjunct to rest and physical therapy).
Drug product profile
- Name: ROBAXIN-750
- Active ingredient: Methocarbamol
- Strength: 750 mg
- Route: Oral
- Drug class: Centrally acting skeletal muscle relaxant
- Indication (typical labeling): Relief of discomfort associated with acute, painful musculoskeletal conditions.
Key commercial implications of being an older generic molecule
- Multi-source availability compresses manufacturer differentiation.
- Demand is sensitive to payer policy for musculoskeletal indications, not to novelty in MoA.
What does the clinical trials pipeline look like for methocarbamol 750 mg (ROBAXIN-750)?
Featured snippet answer: Public registries show low late-stage activity for methocarbamol and limited focus specifically on 750 mg oral dosing in “new” pivotal programs; most activity is historical, small, or non-750-specific.
How to interpret “clinical trials update” for an established generic
For older drugs like methocarbamol, trial signals typically fall into:
- Comparative or formulation studies (bioequivalence, PK, or tolerability)
- Adjunct exploration in broader musculoskeletal pain settings
- Repurposing trials, usually small and not tied to a single marketed strength
Where ROBAXIN-750-specific evidence is usually limited
- Trials rarely target a specific branded strength (750 mg) once multiple generics exist.
- Evidence tends to be molecule-level rather than brand-level, with bioequivalence bridging.
(No specific, verifiable, brand-indexed Phase 2/3 “ROBAXIN-750 (methocarbamol 750 mg)” trial identifiers are provided in the available input, so a definitive trial-by-trial update cannot be reliably produced.)
When does ROBAXIN-750 lose exclusivity and what patents matter?
Featured snippet answer: Methocarbamol products are not protected by meaningful, current brand exclusivity in the way newer drugs are; market access is generally governed by generic manufacturing and FDA approval rather than active patent estates.
Exclusivity vs. patent-driven competition for older generics
- Regulatory exclusivities are typically exhausted for older drugs.
- Patent protection (if any) is often limited to specific formulation/process patents, which is less likely to be a decisive driver for methocarbamol 750 mg oral tablets compared with new molecular entities.
Practical implication for business planning
- Expected competitive behavior is typical multi-source generic: pricing pressure, contracting, and distribution competitiveness.
(A precise Orange Book-driven patent-by-patent exclusivity chart cannot be created from the provided input.)
What is the Orange Book status of ROBAXIN-750 (methocarbamol 750 mg)?
Featured snippet answer: The Orange Book status for methocarbamol products is generally “approved generic/supplemental approvals” with limited remaining exclusivity relevance for market entry decisions.
What “Orange Book status” usually means for methocarbamol
- Listed patents, if present, tend to cover narrow aspects (specific compositions, manufacturing controls, or device-like features).
- For most generic oral solid products, FDA approval and ANDA strategy drive market competition.
(No specific Orange Book listing IDs, patent numbers, or expiration dates are included in the available input, so a complete status table cannot be generated.)
How many competitors sell methocarbamol 750 mg and who holds market share?
Featured snippet answer: Methocarbamol is broadly multi-sourced. Market share typically clusters among major generic manufacturers, wholesalers, and national distributors based on contracting rather than clinical differentiation.
Competitive landscape structure
- Generic manufacturers with broad oral muscle relaxant portfolios
- Large pharmacy distribution channel access
- PBM/formulary tiering as the biggest determinant of unit volume
What drives volume for oral methocarbamol
- Prescriber familiarity
- Formulary placement for musculoskeletal pain adjunct therapy
- Pharmacy stocking and generic switching economics
(No sales-share data for ROBAXIN-750 or methocarbamol 750 mg is included in the provided input, so numeric market shares cannot be reported.)
What is the market size for methocarbamol and how has it been trending?
Featured snippet answer: The methocarbamol market behaves like a mature generic category: volumes are relatively stable, while revenues track unit demand and price erosion.
Market dynamics
- Volume: linked to musculoskeletal injury/strain visits, emergency/urgent care prescribing, and post-procedure pain support.
- Price: subject to generic price competition, wholesaler contract dynamics, and bid-based pharmacy economics.
- Substitution: interchangeability with other muscle relaxants shifts demand based on payer rules and comparative tolerability perceptions.
Scenario framing used in projections
- Base case: modest volume growth or flat demand with continued price erosion.
- Downside: accelerated price competition or formulary downgrade.
- Upside: broader formulary adoption or increased script volume in contracting cycles.
(No category-level historical revenue/units are supplied in the available input, so a numeric model cannot be built.)
What is the revenue and unit projection for ROBAXIN-750 over the next 3–5 years?
Featured snippet answer: Near- to mid-term revenue is most likely to remain flat to low-single-digit growth in units, with revenue constrained by ongoing generic price competition.
Projection logic for a mature, multi-source generic
- Unit demand grows roughly with underlying musculoskeletal care utilization.
- Revenue growth depends on net price retention after contracting and generic mix shift.
- Manufacturer-level performance depends on distribution and formulary placement rather than unique clinical differentiation.
Projection bands (non-quantified due to missing baseline metrics)
- Units: flat to modest growth
- Net revenue: flat to modest decline, then stabilization as supply normalizes
(Quantified projections require baseline volume, ASP/wholesale price, and competitor mix data not provided in the input.)
How does ROBAXIN-750 compare with other oral muscle relaxants?
Featured snippet answer: Methocarbamol is a legacy option within centrally acting skeletal muscle relaxants, usually competing on formulary position, dosing convenience, and payer preference rather than breakthrough clinical advantage.
Comparison axes used by formularies
- Sedation/tolerability profiles as reflected in labeling and clinical practice
- Switching rules within the muscle relaxant class
- Step edits and prior authorization requirements in certain payers
Likely substitution dynamics
- Where gabapentinoids or other adjuncts are restricted, muscle relaxants may see incremental use.
- If plan policies prefer fewer agents or prefer specific molecules, methocarbamol may lose share.
(No specific competitor list, pricing, or formulary status data is provided in the input.)
What generic entry risks exist for methocarbamol 750 mg and how do ANDAs affect pricing?
Featured snippet answer: Additional ANDA approvals typically increase supply and compress net pricing, with the highest impact during periods of new entrants or capacity expansions.
What controls generic entry timing
- ANDA approval timelines
- Patents listed for narrow methods/compositions, if any, can delay certain filings
- Manufacturing readiness and distribution onboarding
How pricing usually behaves after entry
- Rapid net price compression at first
- Then partial stabilization as supply consolidates into fewer effective bidders
(No ANDA/PIVOTAL litigation or patent obstacles for methocarbamol 750 mg are included in the input.)
What patent litigation affects methocarbamol products like ROBAXIN-750?
Featured snippet answer: Methocarbamol litigation is typically limited and does not resemble high-visibility Orange Book battles seen with newer drug platforms; any impact tends to be local to narrow patents or specific generic applicants.
Why litigation is usually muted in this space
- Mature generic molecule
- Lower commercial upside per incremental launch delay
- Broad multi-source availability reduces leverage
(No litigation docket identifiers or settlement references are provided in the input.)
How do formulation, manufacturing, and bioequivalence constraints impact market access?
Featured snippet answer: For an oral tablet like methocarbamol 750 mg, primary barriers are manufacturing controls, ANDA bioequivalence evidence, and stability/compliance rather than novel clinical proof.
Typical technical determinants for ANDA approvals
- Tablet composition and manufacturing process controls
- Dissolution profile alignment and bioequivalence demonstration
- Stability data supporting shelf life
Commercial impact
- Firms with strong supply chains win pharmacy contracting by maintaining availability and avoiding backorders.
(No specific product/manufacturer formulation details are provided in the input.)
Key Takeaways
- ROBAXIN-750 is methocarbamol 750 mg, an established oral muscle relaxant; clinical trial novelty and late-stage pipeline activity are typically limited for this molecule.
- Market performance is mainly determined by generic competition, payer formularies, and distribution economics rather than patent exclusivity.
- For projections, the most likely pattern for a mature multi-source generic is flat-to-modest unit growth and revenue constrained by continued price erosion.
- A detailed exclusivity and patent landscape requires Orange Book identifiers and patent numbers, and a trial-by-trial clinical pipeline requires registry-specific study IDs, none of which are present in the provided input.
FAQs
- Is methocarbamol 750 mg interchangeable with other methocarbamol strengths?
- Do PBMs prefer methocarbamol over cyclobenzaprine or tizanidine on formulary tiers?
- How does bioequivalence testing influence ANDA approval for methocarbamol tablets?
- What typical substitution and switching patterns affect methocarbamol dispensing at retail pharmacies?
- Which distribution and contracting factors most influence net pricing for mature oral generics like methocarbamol?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Methocarbamol studies and results database. National Library of Medicine.
